Regulus Therapeutics’ (RGLS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the biopharmaceutical company’s stock.

Regulus Therapeutics Stock Up 7.2 %

RGLS opened at $1.48 on Friday. Regulus Therapeutics has a twelve month low of $0.83 and a twelve month high of $3.00. The company has a fifty day moving average of $1.28 and a 200-day moving average of $1.46. The stock has a market cap of $96.94 million, a PE ratio of -1.38 and a beta of 1.42.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.20). During the same period last year, the company earned ($0.40) EPS. Sell-side analysts anticipate that Regulus Therapeutics will post -0.88 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Preston Klassen sold 31,445 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $39,620.70. Following the transaction, the insider now owns 36,055 shares of the company’s stock, valued at $45,429.30. This represents a 46.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Christopher Ray Aker sold 38,547 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the completion of the sale, the vice president now directly owns 54,634 shares of the company’s stock, valued at $68,838.84. The trade was a 41.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 223,998 shares of company stock worth $282,237. 4.35% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in shares of Regulus Therapeutics during the third quarter valued at approximately $46,000. PEAK6 LLC acquired a new stake in Regulus Therapeutics in the 4th quarter valued at $95,000. Velan Capital Investment Management LP bought a new stake in Regulus Therapeutics during the 4th quarter valued at $111,000. JPMorgan Chase & Co. raised its holdings in Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 52,059 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 62,549 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.